Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database

Future Med Chem. 2021 Feb;13(4):363-378. doi: 10.4155/fmc-2020-0248. Epub 2021 Jan 8.

Abstract

Background: The SARS-CoV-2 3CLpro is one of the primary targets for designing new and repurposing known drugs. Methodology: A virtual screening of molecules from the Natural Product Atlas was performed, followed by molecular dynamics simulations of the most potent inhibitor bound to two conformations of the protease and into two binding sites. Conclusion: Eight molecules with appropriate ADMET properties are suggested as potential inhibitors. The greatest benefit of this study is the demonstration that these ligands can bind in the catalytic site but also to the groove between domains II and III, where they interact with a series of residues which have an important role in the dimerization and the maturation process of the enzyme.

Keywords: 3CLpro; COVID-19; SARS-CoV-2; futalosine; molecular dynamics; natural product atlas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • Binding Sites
  • Biological Products / pharmacology*
  • COVID-19 / prevention & control
  • COVID-19 Drug Treatment
  • Computational Biology
  • Drug Design
  • Drug Repositioning
  • Humans
  • Ligands
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Nucleosides / pharmacology
  • Peptide Hydrolases / chemistry
  • Protease Inhibitors / chemistry
  • Protein Binding
  • Protein Multimerization
  • SARS-CoV-2 / drug effects*
  • Software
  • Viral Nonstructural Proteins / antagonists & inhibitors

Substances

  • Antiviral Agents
  • Biological Products
  • Ligands
  • Nucleosides
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • futalosine
  • Peptide Hydrolases